Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1

A family of drug transporters: the multidrug resistance-associated proteins

Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751

Gain of function mutations in p53

Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894

Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 669

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

Schuetz, J. D., Connelly, M., Sun, D., Paibir, S. G., Flynn, P. M., Srinivas, R. V., Kumar, A., & Fridland, A. (1999) · Nature Medicine · doi:10.1038/12487 · Cited by 575

Multidrug resistance: molecular mechanisms and clinical relevance

Ling, V. W. T. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051053 · Cited by 525

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 439

Structural, mechanistic and clinical aspects of MRP1

Hipfner, D. R., Deeley, R. G., & Cole, S. P. C. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00168-6 · Cited by 412

A comparison of the biological activities of wild‐type and mutant p53

Zambetti, G. P., & Levine, A. J. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344485 · Cited by 410

p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.

Fan, S., El‐Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K. G., Fornace, A. J., MAGRATH, I. T., Kohn, K. W., & O'Connor, P. M. (1994) · PubMed · Cited by 404

Multiple physiological functions for multidrug transporter P-glycoprotein?

Johnstone, R. W., Ruefli, A. A., & Smyth, M. J. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01493-0 · Cited by 308

Transcriptional Regulation of the MDR1 Gene by Histone Acetyltransferase and Deacetylase Is Mediated by NF-Y

Jin, S. V., & Scotto, K. W. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4377 · Cited by 289

Activation of c- myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain

Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., & Zambetti, G. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3735 · Cited by 194

The MYND Motif Is Required for Repression of Basal Transcription from the Multidrug Resistance 1 Promoter by the t(8;21) Fusion Protein

Lutterbach, B. A., Sun, D., Schuetz, J. D., & Hiebert, S. W. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.6.3604 · Cited by 194

Transcriptional Activation of the Human Epidermal Growth Factor Receptor Promoter by Human p53

Ludes-Meyers, J. H., Subler, M. A., Shivakumar, C. V., Muñoz, R. M., Jiang, P., Bigger, J. E., Brown, D. R., Deb, S. P., & Deb, S. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6009 · Cited by 185

Two Domains of p53 Interact with the TATA-Binding Protein, and the Adenovirus 13S E1A Protein Disrupts the Association, Relieving p53-Mediated Transcriptional Repression

Horikoshi, N., Usheva, A., Chen, J., Levine, A. J., Weinmann, R. S., & Shenk, T. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.1.227 · Cited by 182

p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents

Thottassery, J. V., Zambetti, G. P., Arimori, K., Schuetz, E. G., & Schuetz, J. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.11037 · Cited by 161

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study

Buttitta, F., Marchetti, A., Gadducci, A., Pellegrini, S., Morganti, M., Carnicelli, V., Cosio, S., Gagetti, O., Genazzani, A. R., & Bevilacqua, G. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.38 · Cited by 153

Mutant p53 protein expression interferes with p53-independent apoptotic pathways

Li, R., Sutphin, P. D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., Prokocimer, M., & Rotter, V. (1998) · Oncogene · doi:10.1038/sj.onc.1201867 · Cited by 140

Cloning and Expression of Murine Sister of P-Glycoprotein Reveals a More Discriminating Transporter ThanMDR1/P-Glycoprotein

Lecureur, V., Sun, D., Hargrove, P., Schuetz, E. G., Kim, R. B., Lan, L.-B., & Schuetz, J. D. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26438-5 · Cited by 128

Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells

Sullivan, G. F., Yang, J., Vassil, A. D., Yang, J., Bash-Babula, J., & Hait, W. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9290 · Cited by 124

Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants.

Lin, J., Teresky, A. K., & Levine, A. J. (1995) · PubMed · Cited by 123

The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.

Zastawny, R. L., Salvino, R., Chen, J., Benchimol, S., & Ling (1993) · PubMed · Cited by 118

Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.

Wang, Q., & Beck, W. T. (1998) · PubMed · Cited by 112

p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer

Linn, S., Honkoop, A. H., Hoekman, K., van der Valk, P., Pinedo, H. M., & Giaccone, G. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.316 · Cited by 110

p53 binds to the TATA-binding protein-TATA complex

Martin, D. W., Muñoz, R. M., Subler, M. A., & Deb, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38619-3 · Cited by 106

c-Maf Interacts with c-Myb To Regulate Transcription of an Early Myeloid Gene during Differentiation

Hegde, S. P., Kumar, A., Kurschner, C., & Shapiro, L. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2729 · Cited by 94

`Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain

Lányi, Á., Deb, D., Seymour, R. C., Ludes-Meyers, J. H., Subler, M. A., & Deb, S. (1998) · Oncogene · doi:10.1038/sj.onc.1201857 · Cited by 87

12-O-Tetradecanoylphorbol-13-Acetate Activation of the MDR1 promoter Is Mediated by EGR1

McCoy, C., Smith, D. E., & Cornwell, M. M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.11.6100 · Cited by 85

HSP70 Binding Sites in the Tumor Suppressor Protein p53

Fourie, A. M., Hupp, T. R., Lane, D. P., Sang, B., Barbosa, M. S., Sambrook, J., & Gething, M.-J. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19471 · Cited by 83

Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein

Farmer, G. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.21.4281 · Cited by 74

Expression of calpain I messenger RNA in human renal cell carcinoma: Correlation with lymph node metastasis and histological type

Braun, C., Engel, M., Seifert, M., Theisinger, B., Seitz, G., Zang, K. D., & Welter, C. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990219)84:1 · Cited by 71

Sp1 and Egr-1 Have Opposing Effects on the Regulation of the RatPgp2/mdr1b Gene

Thottassery, J. V., Sun, D., Zambetti, G. P., Troutman, A. G., Sukhatme, V. P., Schuetz, E. G., & Schuetz, J. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.5.3199 · Cited by 61

High local protein concentrations at promoters: Strategies in prokaryotic and eukaryotic cells

Dröge, P., & Müller‐Hill, B. (2001) · BioEssays · doi:10.1002/1521-1878(200102)23:2 · Cited by 60

MBP1: a novel mutant p53-specific protein partner with oncogenic properties

Gallagher, W. M., Argentini, M., Sierra, V., Bracco, L. P., Debüssche, L., & Conseiller, E. (1999) · Oncogene · doi:10.1038/sj.onc.1202937 · Cited by 60

Enterocyte differentiation is compatible with SV40 large T expression and loss of p53 function in human colonic Caco‐2 cells

Djelloul, S., Forgue-Lafitte, M. E., Hermelin, B., Mareel, M. M. K., Bruyneel, E. A., Baldi, A., Giordano, A., Chastre, E., & Gespach, C. P. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00208-1 · Cited by 54

Expression of genes that regulate Fas signalling and Fas-mediated apoptosis in colon carcinoma cells

Tillman, D. M., Harwood, F. G., Gibson, A. A., & Houghton, J. A. (1998) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400369 · Cited by 38

Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer

Fukushima, Y., Oshika, Y., Tokunaga, T., Hatanaka, H., Tomisawa, M., Kawai, K., Ozeki, Y., Tsuchida, T., Kijima, H., Yamazaki, H., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00035-0 · Cited by 36

P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo

Angelis, P. D., Stokke, T., Smedshammer, L., Lothe, R. A., Lehne, G., Chen, Y., & Clausen, O. P. F. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.329 · Cited by 36

Colorectal Cancer and the Intersection between Basic and Clinical ResearchPreprint

Vogelstein, B., & Kinzler, K. W. (1994) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1994.059.01.057 · Cited by 32

Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point.

Wang, L. H., Okaichi, K., Ihara, M., & Okumura, Y. (1998) · PubMed · Cited by 23

Mdr1b facilitates p53-mediated cell death and p53 is required for Mdr1b upregulation in vivo

Lecureur, V., Thottassery, J. V., Sun, D., Schuetz, E. G., Lahti, J. M., Zambetti, G. P., & Schuetz, J. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204065 · Cited by 18

P‐Glycoprotein Is Positively Correlated with p53 Protein Accumulation in Human Colorectal Cancers

Oka, M., Kounoura, K., 楢崎, 史., Sakamoto, A., Fukuda, M., Matsuo, I., Ikeda, K., Tsurutani, J., Ikuno, N., Omagari, K., et al. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00445.x · Cited by 17

p53 mutations in cancer

Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647

Mutant p53: one name, many proteinsPreprint

Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,290

The extraordinary ligand binding properties of human serum albumin

Fasano, M., Curry, S., Terreno, E., Galliano, M., Fanali, G., Narciso, P., Notari, S., & Ascenzi, P. (2005) · IUBMB Life · doi:10.1080/15216540500404093 · Cited by 1,090

Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting

Borrero, L. J. H., & El‐Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 805

Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System

Sarkadi, B., Homolya, L., Szakács, G., & Váradi, A. (2006) · Physiological Reviews · doi:10.1152/physrev.00037.2005 · Cited by 726

The Region 3′ to the Major Transcriptional Start Site of the MDR1 Downstream Promoter Mediates Activation by a Subset of Mutant P53 Proteins

Strauss, B. E., & Haas, M. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2781 · Cited by 33

Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants.

Nguyen, K. T., Liu, B.-Y., Ueda, K., Gottesman, M. M., Pastan, I. H., & Chin, K. (1994) · PubMed · Cited by 54

Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells

Nicoletti, M. I., Myers, T. G., Fojo, T., & Blagosklonny, M. V. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.2.375 · Cited by 5

Mutant p53 cooperates with ETS2 to promote etoposide resistancePreprint

Do, P. M., Varanasi, L., Fan, S., Li, C., Kubacka, I., Newman, V., Chauhan, K. M., Daniels, S. R., Boccetta, M., Garrett, M. R., et al. (2012) · Genes & Development · doi:10.1101/gad.181685.111 · Cited by 201

Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.

Wang, Q., & Beck, W. T. (1998) · PubMed · Cited by 112